Study of high-dose Pitavastatin on lipid and glucose metabolism disorder in Coronary Artery Disease. (Shield-CAD)
- Conditions
- Patients with stable coronary artery disease
- Registration Number
- JPRN-UMIN000008627
- Lead Sponsor
- Minami-Osaka Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Not provided
Exclusion Criteria 1. Patients planed revascularization 2. Patients with occurrence of acute coronary syndrome (AMI or Unstable angina) within 3 months 3. Patients who have been undergone PCI or CABG within 3 months 4. Malignant tumor in active phase 5. Patients who have hypersensitivity to LIVALO, Lipitor, CRESTOR tablet 6) Patients who have severe liver dysfunction or biliary atresia. 7)Patients who are being treated with cyclosporine 8) Pregnant women, women suspected of being pregnant, or lactating women 9. Patients with prohibited drugs 10. Patients who received insulin therapy. 11. Patients who changed diabetes therapy within 3 months before entry. 12. Patients who received cholesterol-lowering agents except statin within a month before entry. 13. Patients undergoing dialysis 14. Patients with familial hypercholesterolemia 15. Patients who are ineligible in the opinion of the investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change and percent change in HbA1c at 3, 6 months after administration
- Secondary Outcome Measures
Name Time Method Change and percent change in TC, LDL-C, HDL-C, TG, Scr, microalbuminuria, eGFR, FBS, IRI, HOMA-IR, ApoA1, ApoB, ApoE and SAA at 3, 6, 9, 15 months after administration.